New ALTG Study ILLUMINATE

Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs). The purpose of the study is to test the effectiveness of a new treatment strategy that combines immunotherapy together with chemotherapy for patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). Please contact altg@lungfoundation.com.au for more information.

Complete the survey.

Upcoming Events
  1. Australian Lung Cancer Conference 2020

    February 19, 2020 - February 21, 2020
  2. ALTG Clinical Trial Concept Development Workshop

    February 19, 2020 @ 9:30 am - 1:00 pm
  3. ALTG Open Scientific Advisory Committee Meeting

    February 19, 2020 @ 2:00 pm - 5:00 pm
  4. ALTG Open Management Advisory Committee Meeting

    February 20, 2020 @ 7:00 am - 8:00 am
  5. ALTG Strategic Planning Workshop

    February 21, 2020 @ 7:00 am - 9:00 am